NEW YORK (GenomeWeb News) – New England Peptide today announced a licensing agreement covering peptide compounds from Atlantic Cancer Research Institute.

NEP has acquired the worldwide rights to Vn96 and other peptide compounds for the research grade enrichment of microparticles, microvesicles, and exosomes. NEP said it plans on releasing a research grade enrichment kit next quarter, and it and ACRI, the co-inventors of Vn96, are looking for collaborators for the clinical use of the synthetic peptide that was designed to catch surface molecules on microvesicles.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.